FDA
- Status: approved
🇺🇸 BNT162b4 5 mcg in United States
BNT162b4 5 mcg (bnt162b4-5-mcg) regulatory status in United States.
Marketing authorisation
Pricing & reimbursement
- annual_list: USD 66.00 per year
BNT162b4 5 mcg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is BNT162b4 5 mcg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for BNT162b4 5 mcg in United States?
Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.
What does BNT162b4 5 mcg cost in United States?
annual_list: USD 66.00 per year. Final patient cost depends on reimbursement and any patient access scheme.